

Cần Thơ, ngày 20 tháng 04 năm 2023  
Cantho, 20<sup>th</sup> April 2023

**CÔNG BỐ THÔNG TIN BẤT THƯỜNG**  
**EXTRAORDINARY INFORMATION DISCLOSURE**

Kính gửi/ *Kind Attn to:* Ủy Ban Chứng Khoán Nhà Nước/ *State Securities Commission*  
Sở Giao Dịch Chứng Khoán Tp. HCM/ *Ho Chi Minh Stock Exchange*

- Tên tổ chức/ *Name of organization:* Công ty Cổ phần Dược Hậu Giang/ *DHG Pharmaceutical JSC*
  - Mã chứng khoán/ *Ticker symbol:* DHG
  - Địa chỉ/ *Address:* 288 Bis Nguyễn Văn Cừ, P. An Hòa, Q. Ninh Kiều, Tp. Cần Thơ  
*288 Bis Nguyen Van Cu, An Hoa Ward, Ninh Kieu District, Cantho City*
  - Điện thoại liên hệ/ *Tel:* 0292 3891 433 Fax: 0292 3895 209
  - E-mail: dhgpharma@dhgpharma.com.vn
- Nội dung thông tin công bố/ *Contents of disclosure:*

Công ty Cổ phần Dược Hậu Giang (DHG Pharma) xin công bố thông tin như sau/ *DHG Pharma would like to disclose information as follows:*

- Quyết định Hội đồng Quản trị (HĐQT) số 010/2023/QĐ.HĐQT ngày 19/04/2023 về việc phê duyệt các giao dịch, hợp đồng giữa Công ty Cổ phần (CTCP) Dược Hậu Giang với tổ chức có liên quan CTCP Chế Tạo Thuốc Taisho (Quyết định HĐQT đính kèm).

*Decision of the Board of Directors (BOD) No. 010/2023/QD.HDQT dated 19 Apr 2023 on approval of the transactions, contracts between DHG Pharma and related party Taisho Pharmaceutical Co., Ltd. (BOD Decision has been enclosed).*



- Ngày đăng-ký cuối cùng chi trả cổ tức năm 2022/ *Record date to pay dividend in 2022:*
  - + Ngày đăng ký cuối cùng: **ngày 04/05/2023**  
*Record date: 04 May 2023*
  - + Mục đích: chi trả cổ tức năm 2022 bằng tiền mặt  
*Purpose: pay dividends in 2022 in cash*
  - + Ngày thanh toán: 12/05/2023  
*Payment date: 12 May 2023*
  - + Tỷ lệ thực hiện: 35%/cổ phiếu (1 cổ phần được nhận 3.500 đồng)  
*Exercise ratio: 35%/share (1 share shall receive VND 3,500)*

3. Thông tin này đã được công bố trên trang thông tin điện tử của công ty vào ngày 20/04/2023 tại đường dẫn [www.dhgpharma.com.vn](http://www.dhgpharma.com.vn)  
*This information was published on the Company's website on the 20<sup>th</sup> of April 2023, as in the link [www.dhgpharma.com.vn](http://www.dhgpharma.com.vn)*  
Chúng tôi xin cam kết các thông tin công bố trên đây là đúng sự thật và hoàn toàn chịu trách nhiệm trước pháp luật về nội dung các thông tin đã công bố.

*We hereby certify that the information provided is true and correct and we bear the full responsibility to the law.*

**Nơi nhận/ Recipients:**

- Như trên/ As above;
- Lưu/ Archived: AT, FN

**TỔNG GIÁM ĐỐC/GENERAL DIRECTOR**



**Toshiyuki Ishii**

## **DECISION**

***(Re: Approval of the transactions, contracts between  
DHG Pharmaceutical JSC and related party Taisho Pharmaceutical Co., Ltd. in 2023)***

### **THE BOARD OF DIRECTORS OF DHG PHARMACEUTICAL JSC**

- Pursuant to the Charter of DHG Pharmaceutical JSC (DHG Pharma) issued on 19 Apr 2021;
- Pursuant to Statement No.009/TTr.DHG-HĐQT dated 10 Apr 2023 of the General Director on the approval of the transactions, contracts between DHG Pharmaceutical JSC and related party Taisho Pharmaceutical Co., Ltd. in 2023;
- Pursuant to Resolution No.007/2023/NQ.HĐQT dated 19 Apr 2023 of the BOD of DHG Pharma,

## **DECISION**

**Article 1:** Approving the transactions, contracts between DHG Pharmaceutical JSC and related party Taisho Pharmaceutical Co., Ltd. (Taisho) in 2023, and ensure the total value of transactions, contracts with Taisho and its subsidiaries in the Taisho Group with a value of less than 25% of the total value of assets recorded in the latest financial statements of DHG Pharmaceutical JSC with the following details:

1. Partner: Taisho Pharmaceutical Co., Ltd.
2. Relationship: Taisho is the parent company of DHG Pharma.
3. Content of transactions:
  - Contracts to purchase goods and services related to the import of products for sale in the Vietnam market.
  - License fee.
  - IT service fee.
  - Purchasing reagents to serve bioequivalence study.
  - Purchasing equipment to serve product research and development.
  - Earned from research service.
  - Other transactions, contracts, and documents with the total value of less than VND 5 billion/year.

**Article 2:** The General Director is assigned to:

- Have the full right to decide to negotiate and sign/adjust/modify/supplement including the cancellation/termination/liquidation and implementation of arising

transactions, contracts between DHG Pharmaceutical JSC and Taisho in 2023 mentioned in Article 1.

- Ensure all transactions, contracts comply with market principles, do not cause conflicts of interests of the parties in accordance with the Charter, related regulations of DHG Pharmaceutical JSC and applicable laws.

**Article 3:** Members of the Board of Directors, Board of Management of DHG Pharma and relevant members, and units are responsible for the implementation of this decision.

This Decision takes effect from the date of signing./.

***Recipients:***

- As Article 3 “for implementation”;
- Archived: BOD Secretary.

**OBO. THE BOARD OF DIRECTORS**

**CHAIRWOMAN**

**Dang Thi Thu Ha**

[NOTICE: This Convocation Notice is a translation of the Vietnamese language original for convenience purpose only, and in the event of any discrepancy, the Vietnamese language original shall prevail.]